Trials Determined to be Unavailable
The trials listed on this page have been determined to be “unavailable”. The YODA Project periodically reevaluates trials that are unavailable at the time of inquiry for the following reasons:
- Trial is ongoing or was completed <18 months ago
- Regulatory approval is not yet received
If reevaluation identifies that a trial can be made available, the original requestor(s) are contacted. A list of reevaluated trials that are now available to request can also be found on this page.
Unavailable trials
| NCT# | Generic or Product Name | Number of Inquiries Received | Reason Trial is Not Available | |
|---|---|---|---|---|
| NCT02670395 | N/A | 1 | Trial is phase 1 | |
| NCT01274507 | N/A | 1 | Trial is phase 1 | |
| NCT03085108 | N/A | 1 | Trial is phase 1 | |
| NCT03180853 | N/A | 1 | Trial ongoing/completed <18 months ago | |
| NCT04080752 | N/A | 1 | Trial ongoing/completed <18 months ago | |
| NCT04644770 | N/A | 1 | Trial ongoing/completed <18 months ago | |
| NCT02663193 | Abiraterone Acetate | 1 | Trial is out of scope (i.e., observational, etc.) | |
| NCT04447040 | Acetaminophen | 1 | Trial ongoing/completed <18 months ago | |
| NCT02564523 | Ad26.ZEBOV | 1 | Regulatory approval not yet received | |
| NCT04436276 | Ad26.COV2.S | 1 | Trial ongoing/completed <18 months ago | |
| NCT04505722 | Ad26.COV2.S | 5 | Trial ongoing/completed <18 months ago | |
| NCT04614948 | Ad26.COV2.S | 2 | Trial ongoing/completed <18 months ago | |
| NCT04765384 | Ad26.COV2.S | 1 | Trial ongoing/completed <18 months ago | |
| NCT02788045 | Ad26.Mos.HIV | 1 | Trial ongoing/completed <18 months ago | |
| NCT03795441 | Ad26.RSV.preF | 1 | Trial is phase 1 | |
| NCT02315703 | Adenovirus Serotype 26 | 1 | Trial ongoing/completed <18 months ago | |
| NCT04908683 | Adenovirus Serotype 26 | 1 | Trial ongoing/completed <18 months ago | |
| NCT04538664 | Amivantamab | 2 | Trial ongoing/completed <18 months ago | |
| NCT02609776 | Amivantamab | 5 | Trial ongoing/completed <18 months ago | |
| NCT03559192 | Aticaprant | 1 | Regulatory approval not yet received | |
| NCT01254773 | Bapineuzumab | 1 | Data cannot be converted to electronic format | |
| NCT01284387 | Bapineuzumab | 1 | Data cannot be converted to electronic format | |
| NCT02354014 | Bedaquiline | 1 | Trial ongoing/completed <18 months ago | |
| NCT04988308 | Bermekimab | 2 | Trial ongoing/completed <18 months ago | |
| NCT04171518 | CAST-102-SYST | 1 | Trial ongoing/completed <18 months ago | |
| NCT01704040 | CNTO3157 | 1 | Trial is phase 1 | |
| JNS001-JPN03 | Concerta | 1 | Trial materials not available in English | |
| NCT03201965 | Daratumumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT03652064 | Daratumumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT03320707 | Daratumumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT01998971 | DARZALEX | 2 | Trial ongoing/completed <18 months ago | |
| NCT02076009 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT02195479 | DARZALEX | 3 | Trial ongoing/completed <18 months ago | |
| NCT02316106 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT02477891 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT02852837 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT02874742 | DARZALEX | 2 | Trial ongoing/completed <18 months ago | |
| NCT03217812 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT03277105 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT03652064 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT03901963 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT02195479 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT01998971 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT03412565 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT05250973 | DARZALEX | 1 | Trial ongoing/completed <18 months ago | |
| NCT03896061 | ECHELON FLEX GST | 1 | Trial is out of scope (i.e., observational, etc.) | |
| NCT00799864 | EDURANT® | 1 | Trial ongoing/completed <18 months ago | |
| NCT00086684 | ELMIRON® | 1 | Data Partner alliance member has not agreed to share | |
| NCT00236990 | ELMIRON® | 1 | Data Partner alliance member has not agreed to share | |
| NCT02365597 | Erdafitinib | 1 | Trial ongoing/completed <18 months ago | |
| NCT03390504 | Erdafitinib | 1 | Trial ongoing/completed <18 months ago | |
| NCT04083976 | Erdafitinib | 1 | Trial ongoing/completed <18 months ago | |
|
Erdafitinib | 1 | Trial is phase 1 | |
| NCT01946204 | ERLEADA | 3 | Trial ongoing/completed <18 months ago | |
| NCT01171898 | ERLEADA | 1 | Regulatory approval not yet received | |
| NCT02489318 | ERLEADA | 3 | Trial ongoing/completed <18 months ago | |
| NCT01780259 | Esketamine | 1 | Trial is phase 1 | |
| NCT01998958 | Esketamine | 1 | Regulatory approval not yet received | |
| NCT02345148 | Esketamine | 1 | Trial is phase 1 | |
| NCT02417064 | Esketamine | 1 | Regulatory approval not yet received | |
| NCT02418585 | Esketamine | 1 | Regulatory approval not yet received | |
| NCT02422186 | Esketamine | 2 | Regulatory approval not yet received | |
| NCT02418585 | Esketamine | 2 | Regulatory approval not yet received | |
| NCT02493868 | Esketamine | 1 | Regulatory approval not yet received | |
| NCT02497287 | Esketamine | 2 | Regulatory approval not yet received | |
| NCT02682225 | Esketamine | 1 | Trial is phase 1 | |
| NCT02857777 | Esketamine | 1 | Trial is phase 1 | |
| NCT03039192 | Esketamine | 1 | Regulatory approval not yet received | |
| NCT04338321 | Esketamine | 1 | Trial ongoing/completed <18 months ago | |
| NCT02919579 | Esketamine | 1 | Trial is phase 1 | |
| NCT03185819 | Esketamine | 1 | Trial ongoing/completed <18 months ago | |
| NCT04599855 | Esketamine | 1 | Trial ongoing/completed <18 months ago | |
| NCT04899336 | ExPEC9V | 1 | Trial ongoing/completed <18 months ago | |
| NCT01964651 | FAAH inhibitor | 1 | Trial is phase 1 | |
| NCT01008553 | Fentanyl | 1 | Trial materials not available in English | |
| NCT01008618 | Fentanyl | 1 | Trial materials not available in English | |
| NCT01703481 | FGFR kinase inhibitor | 1 | Trial is ongoing/completed <18 months ago | |
| NCT02301234 | Fulranumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT03298542 | Golimumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT00925574 | Guselkumab | 1 | Trial is phase 1 | |
| NCT01484587 | Guselkumab | 1 | Trial is phase 1 | |
| NCT01866007 | Guselkumab | 2 | Trial is phase 1 | |
| NCT02155192 | Guselkumab | 1 | Trial is phase 1 | |
| NCT03090100 | Guselkumab | 1 | Regulatory approval not yet received | |
| NCT03466411 | Guselkumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT03998683 | Guselkumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT01109069 | IMBRUVICA | 1 | Data Partner alliance member has not agreed to share | |
| NCT01578707 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT01599949 | IMBRUVICA | 1 | Data Partner alliance member has not agreed to share | |
| NCT01611090 | IMBRUVICA | 1 | Data Partner alliance member has not agreed to share | |
| NCT01646021 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT01704963 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT01779791 | IMBRUVICA | 1 | Data Partner alliance member has not agreed to share | |
| NCT01855750 | IMBRUVICA | 2 | Trial ongoing/completed <18 months ago | |
| NCT01973387 | IMBRUVICA | 1 | Data Partner alliance member has not agreed to share | |
| NCT01980628 | IMBRUVICA | 2 | Regulatory approval not yet received | |
| NCT01744691 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT01325701 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT02165397 | IMBRUVICA | 1 | Regulatory approval not yet received | |
| NCT02910583 | IMBRUVICA | 1 | Trial ongoing/completed <18 months ago | |
| NCT01243073 | Imetelstat | 1 | Regulatory approval not yet received | |
| NCT01731951 | Imetelstat | 1 | Trial ongoing/completed <18 months ago | |
| NCT02426086 | Imetelstat | 1 | Trial ongoing/completed <18 months ago | |
| NCT02598661 | Imetelstat | 2 | Trial ongoing/completed <18 months ago | |
| NCT05574959 | Intraocular lens | 1 | Trial ongoing/completed <18 months ago | |
| NCT00758030 | INVEGA® | 1 | Trial is phase 1 | |
| NCT00791349 | INVEGA® | 1 | Trial is phase 1 | |
| NCT00791622 | INVEGA® | 1 | Trial is phase 1 | |
| NCT03345342 | INVEGA® | 1 | Trial ongoing/completed <18 months ago | |
| N/A (sponsor ID: R092670-JPN-4) | INVEGA® SUSTENNA® | 1 | Trial materials not available in English | |
| NCT01559272 | INVEGA® SUSTENNA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT02065791 | INVOKANA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT04252287 | INVOKANA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT02609776 | JNJ-61186372 | 1 | Trial ongoing/completed <18 months ago | |
| NCT02715011 | JNJ-63709178 | 1 | Trial ongoing/completed <18 months ago | |
| NCT02908906 | JNJ-63723283 | 1 | Trial ongoing/completed <18 months ago | |
| NCT03915379 | JNJ-67571244 | 1 | Trial ongoing/completed <18 months ago | |
| NCT04181827 | Ciltacabtagene autoleucel | 4 | Trial ongoing/completed <18 months ago | |
| NCT03891524 | JNJ-70033093 | 1 | Trial ongoing/completed <18 months ago | |
| NCT04811560 | JNJ-75276617 | 1 | Trial ongoing/completed <18 months ago | |
| NCT05441501 | JNJ-80038114 | 1 | Trial ongoing/completed <18 months ago | |
| NCT02094365 | Lumicitabine | 1 | Regulatory approval not yet received | |
| NCT04577833 | Niraparib | 1 | Trial ongoing/completed <18 months ago | |
| NCT00396565 | PALIPERIDONE® | 2 | Trial materials not available in English | |
| NCT01561898 | PALIPERIDONE® | 1 | Trial materials not available in English | |
| NCT01006265 | Ponesimod | 1 | Regulatory approval not yet received | |
| NCT00855335 | PREZISTA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT01619527 | PREZISTA® | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TMC114-C105) | PREZISTA® | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TMC114-C114) | PREZISTA® | 2 | Trial is phase 1 | |
| N/A (sponsor ID: TMC114-C116) | PREZISTA® | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TMC114-C143) | PREZISTA® | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TMC114IFD1001) | PREZISTA® | 1 | Trial is phase 1 | |
| NCT00814801 | RAZADYNE® | 2 | Trial materials not available in English | |
| N/A (sponsor ID: GAL-JPN-3) |
RAZADYNE® | 1 | Trial materials not available in English | |
| N/A (sponsor ID: GAL-PED-1001 (CR010954)) | RAZADYNE® | 1 | Trial is out of scope (i.e., observational, etc.) | |
| N/A (sponsor ID: RIS-BEL-24) | RISPERDAL® | 1 | Regulatory approval not yet received | |
| N/A (sponsor ID: RIS-INT-26) | RISPERDAL® | 1 | Data cannot be converted to electronic format | |
| NCT00253110 (sponsor ID: RIS-USA-79) | RISPERDAL® | 1 | Data cannot be converted to electronic format | |
| NCT00240708 (sponsor ID: RIS-JPN-S31) | RISPERDAL® | 1 | Data cannot be converted to electronic format | |
| N/A (sponsor ID: RIS-INT-39) | RISPERDAL® | 1 | Regulatory approval not yet received | |
| N/A (sponsor ID: RIS-NED-9) | RISPERDAL® | 1 | Regulatory approval not yet received | |
| NCT00246194 | RISPERDAL CONSTA® | 1 | Trial is phase 1 | |
| NCT00330551 | RISPERDAL CONSTA® | 1 | Trial is phase 1 | |
| NCT04988295 | Rybrevant | 1 | Trial ongoing/completed <18 months ago | |
| NCT03374475 | Seltorexant | 1 | Trial ongoing/completed <18 months ago | |
| NCT04513912 | Seltorexant | 1 | Trial ongoing/completed <18 months ago | |
| NCT04116736 | senofilcon A | 1 | Trial ongoing/completed <18 months ago | |
| NCT00727987 | SIMPONI | 1 | Data Partner alliance member has not agreed to share | |
| NCT00771251 | SIMPONI | 1 | Data Partner alliance member has not agreed to share | |
| NCT04816513 | STELARA | 1 | Trial is phase 1 | |
| NCT03981744 | STELARA | 1 | Trial ongoing/completed <18 months ago | |
| NCT04075591 | STAR S4 IR® Excimer laser System | 1 | Trial is ongoing/completed <18 months ago | |
| NCT03399799 | TALVEY | 1 | Trial is ongoing/completed <18 months ago | |
| NCT04640623 | TAR-200 | 1 | Trial is ongoing/completed <18 months ago | |
| NCT03145181 | TECLISTAMAB | 2 | Trial is phase 1 | |
| NCT04557098 | TECLISTAMAB | 2 | Trial is ongoing/completed <18 months ago | |
| NCT05991960 | TECNIS Odyssey IOL | 1 | Trial is ongoing/completed <18 months ago | |
| NCT02359890 | THERMOCOOL® SMARTTOUCH® (RF ablation treatment) | 1 | Trial ongoing/completed <18 months ago | |
| NCT00236496 | TOPAMAX | 1 | Data cannot be converted to electronic format | |
| NCT00236691 | TOPAMAX | 1 | Data cannot be converted to electronic format | |
| NCT00266591 | TOPAMAX | 1 | Data cannot be converted to electronic format | |
| NCT00236743 | TOPAMAX | 1 | Data cannot be converted to electronic format | |
| NCT00236717 | TOPAMAX | 1 | Data cannot be converted to electronic format | |
| NCT01081795 | TOPAMAX | 2 | Trial materials not available in English | |
| NCT01112267 | Tramadol HCl | 1 | Data cannot be converted to electronic format | |
| NCT02207231 | TREMFYA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT02207244 | TREMFYA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT02641730 | TREMFYA® | 1 | Regulatory approval not yet received | |
| NCT03628924 | TREMFYA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT04882098 | TREMFYA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT04147338 | TREMFYA® | 1 | Trial is phase 1 | |
| NCT03818035 | TREMFYA® | 1 | Trial ongoing/completed <18 months ago | |
| NCT05299606 | Transbronchial Microwave Ablation | 1 | Trial ongoing/completed <18 months ago | |
| N/A (sponsor ID: TRAM-PEDS-001) | ULTRAM ® and ULTRAM® ER | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TRAM-PEDS-005) | ULTRAM® and ULTRAM® ER | 1 | Trial is phase 1 | |
| N/A (sponsor ID: TRAM-PEDS-006) | ULTRAM® and ULTRAM® ER | 1 | Trial is phase 1 | |
| NCT04266756 | UPTRAVI® | 1 | Trial is phase 1 | |
| NCT02627768 | Ustekinumab | 1 | Trial ongoing/completed <18 months ago | |
| NCT00103506 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| NCT00111319 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| NCT00507416 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| NCT00908232 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| NCT00431769 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| PMID: 19036115 | VELCADE® | 1 | Data subject to partner agreement; researcher advised to contact Data Partner | |
| NCT00403767 | XARELTO® | 8 | Data Partner alliance member has not agreed to share | |
| NCT00809965 | XARELTO® | 1 | Data Partner alliance member has not agreed to share and regulatory approval not yet received | |
| NCT00440193 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT00395772 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT00439725 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT00439777 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT00494871 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT01830543 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT01877915 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| NCT02111564 | XARELTO® | 1 | Data Partner alliance member has not agreed to share | |
| N/A | Xylometazoline | 1 | Trial is out of scope (i.e., observational, etc.) | |
| NCT00910754 | ZYTIGA® | 1 | Trial is phase 1 | |
| NCT02230046 | ZYTIGA® | 1 | Trial is phase 1 | |
| NCT03748641 | ZYTIGA® | 2 | Trial ongoing/completed <18 months ago | |
| Total: 201 | Total: 231 |
Reevaluated trials that are now available to request:
| NCT# | Generic or Product Name | Number of Inquiries Received | Reason Trial was Originally Not Available |
| NCT00574288 | DARZALEX | 1 | Trial ongoing/completed <18 months ago |
| NCT01615029 | DARZALEX | 1 | Trial ongoing/completed <18 months ago |
| NCT02252172 | DARZALEX | 3 | Regulatory approval not yet received |
| NCT02951819 | DARZALEX | 1 | Trial ongoing/completed <18 months ago |
| NCT02195869 | IMBRUVICA | 1 | Regulatory approval not yet received |
| NCT01032629 | INVOKANA® | 3 | Regulatory approval not yet received |
| NCT01989754 | INVOKANA® | 3 | Regulatory approval not yet received |
| NCT00488631 | SIMPONI® | 3 | Trial ongoing/completed <18 months ago |
| NCT00265122 | STELARA® | 1 | Regulatory approval not yet received |
| NCT00771667 | STELARA® | 2 | Regulatory approval not yet received |
| NCT01090427 | STELARA® | 1 | Trial ongoing/completed <18 months ago and regulatory approval not yet received |
| NCT01369329 | STELARA® | 1 | Regulatory approval not yet received |
| NCT01369342 | STELARA® | 1 | Regulatory approval not yet received |
| NCT02407236 | STELARA® | 1 | Trial ongoing/completed <18 months ago |
| NCT01343277 | YONDELIS® | 1 | Trial ongoing/completed <18 months ago |
| NCT00887198 | ZYTIGA® | 5 | Trial ongoing/completed <18 months ago |
| NCT01591122 | ZYTIGA® | 1 | Trial ongoing/completed <18 months ago |
| NCT01715285 | ZYTIGA® | 6 | Trial ongoing/completed <18 months ago |
| Total: 18 | Total: 36 |
*Last update: January 1, 2024
Note: Inquiries for trials that were not sponsored by one of the YODA Project’s current partnering Data Partners are not included in either of these lists.